Alnylam’s givosiran gets FDA priority review for acute hepatic porphyria

Givosiran, which has been developed to be subcutaneously administered, targets aminolevulinic acid synthase 1 (ALAS1). According to Alnylam, monthly administration of the investigational RNAi therapeutic can potentially reduce

The post Alnylam’s givosiran gets FDA priority review for acute hepatic porphyria appeared first on Pharmaceutical Business review.